Article in Blood cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
30 authors.
Camila Guerrero *Cancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0000-0003-1395-5140
Maria-Jose Larrayoz *Cancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0000-0003-0667-1959
Irache ErdozainCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0009-0009-0446-2134
Noemi PuigHospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, Spain.ORCID 0000-0001-7535-3861
Maria-Teresa CedenaHospital Universitario 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, Spain.ORCID 0000-0001-5851-3720
Catarina MaiaCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0000-0003-3546-1782
Amagoia MañuCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0009-0001-0014-2557
Natalia GordilloCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0009-0000-0466-2093
Oihane ChurrucaCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0009-0003-1235-4981
Diego AlignaniCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0000-0003-0241-1375
Sarai SarvideCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0000-0003-3528-9329
Iria VazquezCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0000-0003-0027-6384
Cristina PerezCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0000-0003-3586-2666
Albert OriolHospital Universitari Germans Trias i Pujol de Badalona, Barcelona, Spain.ORCID 0000-0001-6804-2221
Valentin CabañasHospital Universitario Virgen de la Arrixaca, IMIB-Pascual Parrilla, Murcia, Spain.ORCID 0000-0002-6248-2549
Maria-Jose CalasanzCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0000-0002-0374-3008
Joaquin Martinez-LopezHospital Universitario 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, Spain.ORCID 0000-0001-7908-0063
Maria-Victoria MateosHospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, Spain.ORCID 0000-0003-2390-1218
Juan-Jose LahuertaHospital Universitario 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, Spain.ORCID 0000-0002-3393-9570
Jesus F San-MiguelCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0000-0002-9183-4857
Bruno PaivaCancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.ORCID 0000-0003-1977-3815
Funding
Cancer Research UK (CRUK) C355/A26819European Commission (EC) Mission Cancer grant 101097094 (ELMUMY)Fondazione AIRC per la ricerca sul cancro ETS (AIRC) EDITORFondazione Regionale per la Ricerca Biomedica (FRRB)Fundación Científica Asociación Española Contra el Cáncer (AECC) INVES211176MARTHORIZON EUROPE European Research Council (ERC) 2015 Starting Grant (MYELOMANEXT grant 680200)Instituto de Salud Carlos III (ISCIII) CB16/12/00233International Myeloma Foundation (IMF) Black Swan Research InitiativeRiney Family Multiple Myeloma Research Program Fund
6 · The paper itself
Abstract
significanceSPMs that develop in patients with multiple myeloma have a deleterious impact on survival. Patients with CH may be at risk of developing SPMs, which could potentially be avoided through individualized treatment. However, our results suggest that screening for CH at diagnosis has limited utility.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma. · full record | OpenQuestion